Document is current
Any future updates will be listed below
-
Authors
Wallman, Johan Karlsson https://orcid.org/0000-0002-4915-2924
Mogard, Elisabeth https://orcid.org/0000-0002-5706-203X
Sagard, Jonas https://orcid.org/0000-0001-7227-0665
Andréasson, Kristofer https://orcid.org/0000-0001-7021-2541
Marsal, Jan https://orcid.org/0000-0003-4808-0014
Inci, Fatih https://orcid.org/0000-0001-8629-588X
Geijer, Mats https://orcid.org/0000-0003-0529-7723
Olofsson, Tor https://orcid.org/0000-0002-9919-4487
Lindqvist, Elisabet https://orcid.org/0000-0002-9937-6352
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 28 September 2025
First Online: 21 October 2025
Declarations
:
: Ethical approval was granted by the Regional Ethics Committee in Lund, Sweden (Dnr:2015/436). Oral and written informed consent was acquired before entry into the study, which was performed in accordance with the Helsinki Declaration.
: Not applicable.
: JKW: Speakers bureau: AbbVie, Amgen; Grant/research support: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. EM: Speakers bureau: AbbVie, Novartis. JS: None declared. KA: None declared. JM: Speakers bureau: AbbVie, Amgen, Bayer, Biogen, BMS, Ferring, Galapagos, ITH, Janssen, Lument, MSD, Otsuka, Pfizer, Sandoz, Takeda, Tillotts, UCB; Grant/research support: AbbVie, BMS, Calpro AS, Carbiotix, Ferring, Fresenius Kabi, Pfizer, Svar Life Science, Takeda. FI: None declared. MG: Speakers bureau: AbbVie, UCB. TO: Consultant: Eli Lilly, MSD. EL: None declared.
